48812.1 IP-LS

Résumé

Development of specific cell therapy to treat neurological diseases

Textes supplémentaires

Abstract

Chimeric structure of astrocytic specific chaperone and GliaPharm#s lead molecules will be designed by Prof. Raymond evaluated by Prof. Volterra and their potency as drug tested in GliaPharm#s laboratory in a preclinical mouse models including refractory epilepsy.

Participants

Sylvain Lengacher

Wirtschaftspartner

sylengach@gliapharm.com

Gliapharm SA Sylvain Lengacher Ch. des Mines 9 1202 Geneva GE CH

Jean-Louis Reymond

Kontaktperson

reymond@ioc.unibe.ch

Universität Bern Department of Chemistry and Biochem Jean-Louis Reymond Freiestrasse 3 3012 Bern BE CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2021-01-31
Date de fin: 2022-07-31
Coûts totaux approuvés: CHF 334779.37
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

T410 Pharmaceuticals and related technologies 100.0%